KCNC4 and Parkinson disease: Collectively, despite the limitative lack of similar data obtained in human samples, these preclinical findings suggest that the early KV3.4 overexpression could take part not only in PD pathogenesis but also in the different vulnerability of the midbrain and striatum, highlighting KV3.4 as a possible new therapeutic target in PD.